Testing effectiveness (Phase 2)Ended earlyNCT03822117
What this trial is testing
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Who this might be right for
Solid Tumor Malignancy
Incyte Corporation 111